Case 3: Practical Considerations for Use of Sacituzumab Govitecan
Ruta Rao, MD, discusses practical considerations regarding the use of sacituzumab govitecan in patients with relapsed/refractory TNBC.
Case 3: Residual Disease in TNBC and Treatment Considerations
The panel of experts share their treatment recommendations for patients with residual disease after an incomplete response to TNBC therapy.
Case 3: Implications of Residual Disease on TNBC Outcomes
Pathologist David G. Hicks, MD, discusses the impact of residual disease in breast cancer treatment outcomes.
Case 3: 48-Year-Old Woman With Stage T2N1 TNBC
Elizabeth Mittendorf, MD, PhD, and Ruta Rao, MD, present the case of a 48-year-old woman with stage T2N1 TNBC.
Case 3: HER2+ Breast Cancer With Brain Metastases
Carey Anders, MD, presents a case that focuses on a patient with HER2+ breast cancer and brain metastases.
Case 3: Role of Margetuximab in HER2+ Breast Cancer
Experts in the field of breast cancer review the place in therapy for margetuximab.
Case 2: Study Design and Data for PARP Inhibitors in TNBC
Experts in the management of breast cancer review clinical trial data using PARP inhibitors in the treatment of BRCA1/2-mutated TNBC.
Case 3: Treatment for HER2+ Breast Cancer Progression in Viscera
The panel of experts in breast cancer discusses the treatment options for a patient with systemic progression of HER2+ disease on T-DM1 and no CNS metastases.
Case 3: Treatment Options for CNS Progression in HER2+ Breast Cancer
Experts in the management of breast cancer discuss the role of tucatinib in patients with brain metastases.
Case 2: Considerations for PARP Inhibitor Use in TNBC
Experts in the management of breast cancer review some treatment considerations surrounding the use of PARP inhibitors in BRCA1/2–positive triple-negative breast cancer.
Case 2: 34-Year-Old Woman With TNBC
Elizabeth Mittendorf, MD, PhD, presents the case of a 34-year-old woman with PD-L1–positive triple-negative breast cancer.
Future of PI3K Inhibitors in RR FL and MZL
Expert hematologist/oncologists provide thoughts on the potential role of PI3K inhibitors in managing R/R FL and MZL, as well as other diseases.
Emerging Combinations and Novel Agents for RR FL and MZL
Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, discuss the role of PI3K inhibitor combination therapy and novel agents on the horizon for the treatment of R/R FL and MZL.
Case 1: Treatment Recommendations for PD-L1+ TNBC
The panel discusses treatment options and considerations for a 53-year-old woman with PD-L1+ triple-negative breast cancer.
Case 2: Recurrence of HER2+ Breast Cancer After 12 Months
Carey Anders, MD, and Andrew Seidman, MD, share their recommendations for HER2+ breast cancer recurrence within 12 months of HP.
Case 1: KEYNOTE-355 Trial Design and Considerations
The panel of experts review the study design and key efficacy data of the KEYNOTE-355 trial.
Case 2: Treatment Options at Recurrence of HER2+ Breast Cancer After 5 Years
The panel of experts in breast cancer discuss treatment options when the cancer has metastasized.
Case 1: IMpassion 130 Trial Design and Results
Experts in breast cancer discuss efficacy data from the IMpassion130 clinical trial.
Case 1: 53-Year-Old Woman With TNBC
Elizabeth Mittendorf, MD, PhD, reviews the case of a 53-year-old woman with PD-L1+ TNBC breast cancer and the panel discusses relevant clinical trial data.
Case 2: Recurrence in High-Risk HR+/HER2+ Breast Cancer
Ingrid Mayer, MD, MSCI, presents the case of a patient with high-risk HR+/HER2+ breast cancer who develops recurrence after a long disease-free interval.
Case 2: Considerations for Optimizing Therapy in High Risk MF
Ruben Mesa, MD, and panel discuss considerations for optimizing therapy in high risk myelofibrosis.
Case 2: Efficacy and Safety of Fedratinib in High Risk MF
Experts in myelofibrosis present safety and efficacy data from a clinical trial of fedratinib in patients with high risk myelofibrosis.
Case 2: Safety and Efficacy of Ruxolitinib in High Risk MF
Dr Jamile Shammo presents clinical trial data on the efficacy and safety of ruxolitinib in patients with high risk myelofibrosis.
Case 2: Predictors of Response to Ruxolitinib in High Risk MF
Experts in MPN review data on predictors of response to ruxolitinib in high risk myelofibrosis.
Case 2: Prognostic Models of MF
Jamile Shammo, MD, reviews prognostic models in myelofibrosis.
Case 2: High Risk Myelofibrosis (MF)
Dr Jamile Shammo reviews the case of a 72-year-old man with primary myelofibrosis.
Envisioning the Role of Combination Therapy in the Treatment of CLL: A Q&A With Philip Thompson, MB, BS
Targeting different pathways may dramatically reduce the risk of resistance emergence and improve outcomes.
Case 1: Novel Therapeutic Approaches in High-Risk, Early Stage HER2+ Breast Cancer
Experts in the management of breast cancer review some trials leading to the future of personalized treatment for HER2+ breast cancer.
Case 1: Assessment of Risk of Recurrence in HER2+ Breast Cancer
Andrew Seidman, MD, follows the patient after TCHP therapy and discusses the risk of recurrence with the experts.
Case 1: Subcutaneous HP Therapy in HER2+ Breast Cancer
Ingrid Mayer, MD, MSCI, and panel share the benefits of subcutaneous HP instead of IV HP therapy, particularly for the patients’ quality of life.